{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Clearpoint Neuro, Inc.
Clearpoint Neuro, Inc. Hits New 52-Week High of $29.85
Clearpoint Neuro, Inc. has achieved a new 52-week high of USD 29.85, reflecting a remarkable 415.68% increase over the past year. With a market capitalization of USD 311 million, the company operates in a competitive biotechnology sector, showcasing significant growth potential despite challenging financial metrics.
Clearpoint Neuro Reaches New 52-Week High of $28.80, Up 377%
Clearpoint Neuro, Inc. has achieved a new 52-week high, reflecting a significant year-over-year stock performance increase. With a market capitalization of USD 311 million, the company operates at a loss, indicated by its negative price-to-earnings ratio. This milestone emphasizes the volatility and potential in the biotechnology sector.
Clearpoint Neuro, Inc. Hits New 52-Week High of $22.38
Clearpoint Neuro, Inc. has achieved a new 52-week high of USD 22.38, marking a substantial increase over the past year. With a market capitalization of USD 311 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.
Clearpoint Neuro Hits New 52-Week High of $21.76, Up 275% Yearly
Clearpoint Neuro, Inc. has achieved a new 52-week high of USD 21.76, reflecting a significant increase over the past year. With a market capitalization of USD 311 million, the company operates in a competitive biotechnology sector, despite facing challenges such as negative return on equity and a high price-to-book ratio.
Clearpoint Neuro Hits New 52-Week High of $21.57, Up 243.9%
Clearpoint Neuro, Inc. has achieved a new 52-week high of USD 21.57, reflecting a notable increase of 243.9% over the past year. With a market capitalization of USD 311 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.
Clearpoint Neuro Reaches New 52-Week High of $20.94, Up 235.89%
Clearpoint Neuro, Inc. has achieved a new 52-week high, reflecting a significant increase over the past year. With a market capitalization of USD 311 million, the company operates in a competitive biotechnology sector but is currently not profitable, as indicated by its negative return on equity.
Is Clearpoint Neuro, Inc. technically bullish or bearish?
As of September 12, 2025, Clearpoint Neuro, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly year-to-date with a return of -26.20% compared to the S&P's 12.22%.
Is Clearpoint Neuro, Inc. technically bullish or bearish?
As of June 2, 2025, the trend is mildly bearish due to bearish weekly MACD and KST indicators, despite bullish monthly signals, indicating a cautious outlook with short-term weakness and longer-term potential.
Who are in the management team of Clearpoint Neuro, Inc.?
As of March 2022, the management team of Clearpoint Neuro, Inc. includes Chairman Kimble Jenkins, CEO Joseph Burnett, Lead Independent Director R. John Fletcher, and several Independent Directors: Pascal Girin, B. Kristine Johnson, Matthew Klein, and Timothy Richards. They oversee the company's strategic direction and operations.
What does Clearpoint Neuro, Inc. do?
Clearpoint Neuro, Inc. is a medical device company specializing in minimally invasive surgical procedures in the brain and heart using MRI guidance. As of March 2025, it reported net sales of $8 million and a net loss of $6 million, with a market cap of $315.72 million.
How big is Clearpoint Neuro, Inc.?
As of Jun 18, Clearpoint Neuro, Inc. has a market capitalization of 315.72 million and reported net sales of 32.23 million with a net profit of -20.80 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
